Back

Mavacamten use in a real-world cohort of obstructive hypertrophic cardiomyopathy patients: insights from the initial centre experience

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (2) Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Maria Rita Lima

Hospital Santa Cruz, Lisbon (Portugal)

7 More presentations in this session

Presentation thumbnail
Recognizing red flags: don't judge a book by its cover. data from a multicentric nationwide study
Doctor A. Pinho (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Estimating hypertrophic cardiomyopathy genotype pre-test probability: an online calculator
Mr P. Kopp (Stony Brook, US)
Abstract Slides Video
Presentation thumbnail
Differentiating clinical trial endpoints in transthyretin cardiac amyloidosis is significantly improved with continuing medical education
Doctor C. Rohani-Montez (London, GB)
Abstract Slides Video
Presentation thumbnail
Effect of TTR stabilisers on strain values derived by echocardiography in patients with wild type ATTR Amyloidosis
Doctor J. Westphal (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Changes in global myocardial work indices during mavacamten treatment in obstructive hypertrophic cardiomyopathy
Professor R. Sepp (Szeged, HU)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Reduction of >100 mmHg left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy during mavacamten treatment already after one week of treatment
thumbnail
Congress Presentation
Mavacamten in hypertrophic cardiomyopathy: use of accessible functional testing to examine real-world effectiveness
thumbnail
Congress Presentation
Echocardiographic evolution of symptomatic patients with obstructive hypertrophic cardiomyopathy treated with mavacamten: experience of a portuguese terciary care center

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources